Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Francesco De Cesaris

Showing results (61-70 of 65) with videos related to

Pageof 7
Sort By:
You have reached the last page of results.This site can display upto 65 results.
CNS Drugs|November 24, 2023
Long-Term Treatment Over 52 Weeks with Monthly Fremanezumab in Drug-Resistant Migraine: A Prospective Multicenter Cohort StudyValeria Caponnetto, Antonio Russo, Marcello Silvestro, et al.
Frontiers in Neurology|September 22, 2025
Sex differences in the clinical features of 2,841 patients with migraine: a <i>post-hoc</i>, multicenter, cross-sectional studyMarina Romozzi, Luigi Francesco Iannone, Marcello Silvestro, et al.
Cephalalgia : an International Journal of Headache|June 26, 2026
SafeTy and effectiveness of Atogepant accoRding to the IHS outcome categories: A multicentric, prospective observational study in real life (the 24-week STAR study)Claudia Altamura, Luigi Francesco Iannone, Flavia Lo Castro, et al.
Cephalalgia : an International Journal of Headache|February 13, 2026
Levels of migraine controls following International Headache Society (IHS) recommendations with eptinezumab: Effectiveness and tolerability in a 24-week, prospective multicenter study (the TACHIS study)Luigi Francesco Iannone, Elisa Maria Piella, Danilo Antonio Montisano, et al.
Cephalalgia : an International Journal of Headache|March 25, 2026
The chronopharmacology of atogepant in migraine prevention: A real-world evaluation of influence of timing of administration on effectiveness and tolerabilityLuigi Francesco Iannone, Gabriele Sebastianelli, Federico De Santis, et al.
Pageof 7

Showing results (61-70 of 65) with videos related to

Sort By:
Pageof 7
You have reached the last page of results.This site can display upto 65 results.
CNS Drugs|November 24, 2023
Long-Term Treatment Over 52 Weeks with Monthly Fremanezumab in Drug-Resistant Migraine: A Prospective Multicenter Cohort StudyValeria Caponnetto, Antonio Russo, Marcello Silvestro, et al.
Frontiers in Neurology|September 22, 2025
Sex differences in the clinical features of 2,841 patients with migraine: a <i>post-hoc</i>, multicenter, cross-sectional studyMarina Romozzi, Luigi Francesco Iannone, Marcello Silvestro, et al.
Cephalalgia : an International Journal of Headache|June 26, 2026
SafeTy and effectiveness of Atogepant accoRding to the IHS outcome categories: A multicentric, prospective observational study in real life (the 24-week STAR study)Claudia Altamura, Luigi Francesco Iannone, Flavia Lo Castro, et al.
Cephalalgia : an International Journal of Headache|February 13, 2026
Levels of migraine controls following International Headache Society (IHS) recommendations with eptinezumab: Effectiveness and tolerability in a 24-week, prospective multicenter study (the TACHIS study)Luigi Francesco Iannone, Elisa Maria Piella, Danilo Antonio Montisano, et al.
Cephalalgia : an International Journal of Headache|March 25, 2026
The chronopharmacology of atogepant in migraine prevention: A real-world evaluation of influence of timing of administration on effectiveness and tolerabilityLuigi Francesco Iannone, Gabriele Sebastianelli, Federico De Santis, et al.
Pageof 7